Literature DB >> 2605956

First identification of a gene defect for hypophosphatasia: evidence that alkaline phosphatase acts in skeletal mineralization.

M J Weiss1, D E Cole, K Ray, M P Whyte, M A Lafferty, R Mulivor, H Harris.   

Abstract

Hypophosphatasia is a heritable disorder characterized by defective osteogenesis and deficient liver/bone/kidney alkaline phosphatase (L/B/K ALP) activity. Severe forms of the disease are inherited in an autosomal recessive fashion. We examined cultured skin fibroblasts from twelve patients with severe hypophosphatasia. All were deficient in L/B/K ALP activity, yet produced normal levels of the corresponding mRNA. Sequence analysis of L/B/K ALP cDNA isolated from one of the patient-derived fibroblast lines revealed a point mutation that converted amino acid 162 of mature L/B/K ALP from alanine to threonine. The patient was homozygous and the parents, who are second cousins, heterozygous for this mutation. Introduction of the mutation into an otherwise normal cDNA disrupted the expression of active enzyme, demonstrating that a defect in the L/B/K ALP gene resulted in hypophosphatasia and that the enzyme is, therefore, essential for normal skeletal mineralization.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605956     DOI: 10.3109/03008208909050000

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  5 in total

1.  Coordinate inhibition of alkaline phosphatase and type X collagen syntheses by 1,25-dihydroxyvitamin D3 in primary cultured hypertrophic chondrocytes.

Authors:  S Inao; H E Conrad
Journal:  Calcif Tissue Int       Date:  1992-05       Impact factor: 4.333

Review 2.  Biomineralization and matrix vesicles in biology and pathology.

Authors:  Ellis E Golub
Journal:  Semin Immunopathol       Date:  2010-12-08       Impact factor: 9.623

Review 3.  Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.

Authors:  S A Bowden; B L Foster
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia.

Authors:  H J Girschick; P Schneider; I Haubitz; O Hiort; H Collmann; M Beer; Y S Shin; H W Seyberth
Journal:  Orphanet J Rare Dis       Date:  2006-06-28       Impact factor: 4.123

5.  Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy.

Authors:  Hermann J Girschick; Etienne Mornet; Meinrad Beer; Monika Warmuth-Metz; Peter Schneider
Journal:  BMC Pediatr       Date:  2007-01-23       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.